Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/08/26
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/26
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026Seeking Alpha • 12/23/25
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusGlobeNewsWire • 12/22/25
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare ConferenceGlobeNewsWire • 11/19/25
Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements TranscriptSeeking Alpha • 11/13/25
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/12/25
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025GlobeNewsWire • 11/07/25
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025GlobeNewsWire • 11/05/25
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025GlobeNewsWire • 10/22/25
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025GlobeNewsWire • 10/07/25
Atea Pharmaceuticals, Inc. (AVIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferenceGlobeNewsWire • 09/02/25
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/25
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025GlobeNewsWire • 07/31/25
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North AmericaGlobeNewsWire • 06/24/25
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/25
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025GlobeNewsWire • 05/07/25
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025GlobeNewsWire • 04/23/25
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase ProgramGlobeNewsWire • 04/17/25
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusGlobeNewsWire • 04/09/25